WallStSmart

AbbVie Inc (ABBV)vsElevance Health Inc (ELV)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Elevance Health Inc generates 212% more annual revenue ($201.11B vs $64.39B). ABBV leads profitability with a 9.8% profit margin vs 2.5%. ABBV appears more attractively valued with a PEG of 0.54. ABBV earns a higher WallStSmart Score of 73/100 (B).

ABBV

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 8.5Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

ELV

Buy

55

out of 100

Grade: C-

Growth: 4.0Profit: 5.0Value: 5.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.66
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-86.7%)

Margin of Safety

-86.7%

Fair Value

$152.97

Current Price

$290.89

$137.92 premium

UndervaluedFair: $152.97Overvalued
ELVOvervalued (-6.1%)

Margin of Safety

-6.1%

Fair Value

$414.67

Current Price

$414.41

$0.26 premium

UndervaluedFair: $414.67Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$504.37B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
40.0%10/10

Strong operational efficiency at 40.0%

EPS GrowthGrowth
290.4%10/10

Earnings expanding 290.4% YoY

Debt/EquityHealth
-11.9310/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.548/10

Growing faster than its price suggests

ELV2 strengths · Avg: 8.5/10
Market CapQuality
$92.88B9/10

Large-cap with strong market position

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Areas to Watch

ABBV2 concerns · Avg: 2.0/10
P/E RatioValuation
80.6x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

ELV4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.4%4/10

1.4% revenue growth

Profit MarginProfitability
2.5%3/10

2.5% margin — thin

Operating MarginProfitability
4.6%3/10

Operating margin of 4.6%

EPS GrowthGrowth
-13.1%2/10

Earnings declined 13.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.54 suggests the stock is reasonably priced for its growth.

Bull Case : ELV

The strongest argument for ELV centers on Market Cap, Price/Book. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bear Case : ABBV

The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 80.6x leaves little room for execution misses.

Bear Case : ELV

The primary concerns for ELV are Revenue Growth, Profit Margin, Operating Margin. Thin 2.5% margins leave little buffer for downturns.

Key Dynamics to Monitor

ELV carries more volatility with a beta of 0.71 — expect wider price swings.

ABBV is growing revenue faster at 10.2% — sustainability is the question.

ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABBV scores higher overall (73/100 vs 55/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Elevance Health Inc

HEALTHCARE · HEALTHCARE PLANS · USA

Elevance Health Inc. is a health benefits company. The company is headquartered in Indianapolis, Indiana.

Want to dig deeper into these stocks?